Top Diabetes Stocks Worth Buying: Market Growth Creates Investment Opportunity

The diabetes treatment sector has experienced a notable shift since late 2023, with concerns about weight-loss drug competition giving way to a more optimistic outlook. Major companies in this space reported stronger-than-expected results, particularly regarding how GLP-1 medications actually complement rather than cannibalize demand for glucose monitoring devices. With the global diabetes care market projected to expand to $223 billion by 2032 from $89.2 billion in 2022, the recent market pullback has created an attractive entry point for investors seeking exposure to this high-growth sector. Here we examine three leading diabetes stock opportunities that stand to benefit from this expanding market.

Tandem Diabetes Care: Innovation Leading Growth Momentum

Tandem Diabetes Care (NASDAQ: TNDM) represents a compelling case for diabetes stock investors focused on product innovation. In mid-2024, Citi upgraded the company to “buy,” citing enthusiasm around Tandem’s new Mobi insulin delivery system. The research firm noted that early adoption of Mobi is outpacing market expectations, signaling strong commercial potential.

The company’s financial performance underscores this momentum. Tandem delivered 12% year-over-year sales growth in its recent quarter—above Street forecasts—with management guiding for consistent 12% sales growth through the year. Citi views this guidance as conservative, suggesting significant room for upside surprise. Additionally, the anticipated integration of Tandem’s products with glucose monitoring systems from competitors represents a potential catalyst for further appreciation.

Institutional investor interest in TNDM remains robust, reflected in an A- accumulation/distribution rating from Investor’s Business Daily. The stock’s relative strength score of 96 indicates substantial outperformance relative to peers, demonstrating how well-positioned this diabetes stock has been among sophisticated market participants.

Insulet Corporation: Strong Analyst Support and Market Expansion

Insulet Corporation (NASDAQ: PODD) has attracted heightened analyst attention as a diabetes stock beneficiary of expanding insulin pump adoption. Redburn Atlantic, the research division of Rothschild & Co, initiated coverage with a “buy” rating and $235 price target, recognizing the company’s leadership in automated insulin delivery.

Market research reveals compelling endocrinologist sentiment: 76% of surveyed physicians indicated they would recommend Insulet’s flagship Omnipod 5 system for patients requiring substantial insulin doses. This clinical enthusiasm translates into robust business fundamentals. The insulin pump market is forecast to expand at a 13% compound annual growth rate between 2023 and 2028, providing a favorable backdrop for market share gains.

Insulet’s financial trajectory reinforces the growth narrative. Operating income surged 52% year-over-year to $56.9 million in the recent quarter. Analysts’ consensus forecasts earnings per share rising to $3.73 in 2025 from $3.08 in 2024—a meaningful 21% increase that underscores confidence in the company’s execution. For diabetes stock investors seeking exposure to insulin delivery innovation, Insulet’s combination of strong clinical adoption and rising profitability presents an attractive risk-reward profile.

Dexcom: Market Dominance and Continued Expansion Potential

Dexcom (NASDAQ: DXCM) commands the continuous glucose monitoring market with formidable competitive positioning that positions it as a premier diabetes stock holding. Wells Fargo’s recent survey of 50 endocrinologists projects Dexcom’s weighted average market share rising from 55% in 2023 to 58% in 2025—reflecting gradual share gains even from an already-dominant position.

The bank’s analysis identifies significant expansion opportunity: continuous glucose monitor penetration remains low among certain diabetes patient populations, and Dexcom’s ability to capture these underpenetrated segments could drive sustained growth. RBC Capital, which initiated “outperform” coverage in early 2024, similarly emphasizes the expanding total addressable market and positions Dexcom among the fastest-growing large-cap medical technology companies.

Recent financial results justify this optimistic outlook. Dexcom’s net income increased roughly threefold to $146.4 million compared to $48.6 million a year earlier, while revenue advanced 24% to $921 million. This combination of strong revenue growth and significant operating leverage demonstrates the scalability of the business model and explains why this diabetes stock remains attractive to growth-oriented investors.

Timing the Opportunity in Diabetes Stocks

The convergence of favorable market trends—including adoption of continuous glucose monitoring systems, insulin pump innovation, and expanding GLP-1 medication use—creates a substantial growth runway for leading diabetes stocks. The recent correction in valuations of companies like Tandem, Insulet, and Dexcom offers a compelling opportunity for long-term investors to establish or expand positions in this high-growth sector at more attractive entry prices.